Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

COV-BARRIER
  NCT04421027		 RCTbaricitinibplaceboCOVID 19 hospitalizedlow
764/761 suggested
  • suggested 43 % decrease in deaths,deaths (time to event analysis only),death D28 with a high degree of certainty due to low risk of bias
  • inconclusive 12 % increase in clinical deterioration (PE) with a high degree of certainty due to low risk of bias
  • suggested 25 % increase in clinical improvement with a high degree of certainty due to low risk of bias
  • suggested 28 % increase in clinical improvement (14-day) with a high degree of certainty due to low risk of bias
STOP-COVID (Guimarães)
  NCT04469114		 RCTtofacitinibplaceboCOVID 19 hospitalizedlow
144/145 conclusif
  • demonstrated 37 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
ACTT-2 (Kalil)
  NCT04401579		 RCTbaricitinibplaceboCOVID 19 hospitalizedlow
515/518 conclusif
  • demonstrated 16 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a high degree of certainty due to low risk of bias
  • suggested 31 % decrease in death or ventilation with a high degree of certainty due to low risk of bias
  • suggested 36 % decrease in mechanical ventilation with a high degree of certainty due to low risk of bias

COVID 19 all comers meta-analysis

RECOVERY
  NCT04381936		 RCTbaricitinibstandard of careCOVID 19 all comerssome concern
4148/4008 conclusif
  • demonstrated 13 % decrease in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 10 % decrease in death or ventilation with a moderate degree of certainty due to some concern in risk of bias

COVID-19 mild to moderate meta-analysis

Murugesan RCTtofacitinibstandard of careCOVID-19 mild to moderateNA
50/50 inconclusive
    Rodriguez-Garcia
          EUPAS34966    		 OBSbaricitinibstandard of careCOVID-19 mild to moderateNA
    		62/50 no results
      Cantini OBSbaricitinibstandard of careCOVID-19 mild to moderatecritical
      		113/78 suggested
      • suggested 22.9-fold increase in hospital discharge but with a very low degree of certainty due to critical risk of bias

      COVID-19 severe or critically meta-analysis

      COV-BARRIER (critically ill)
              NCT04421027      		 RCTbaricitinibplaceboCOVID-19 severe or criticallylow
      		51/50 suggested
      • suggested 46 % decrease in deaths,death D28 with a high degree of certainty due to low risk of bias
      • suggested 1.9-fold increase in clinical improvement with a high degree of certainty due to low risk of bias
      DEVENT unpublished
              NCT04377620      		 RCTruxolitinibplaceboCOVID-19 severe or criticallyNA
      		-/- suggested
      • suggested 53 % decrease in deaths
      Tziolos OBSbaricitinibstandard of careCOVID-19 severe or criticallyNA
      		193/176 suggested
      • suggested 7 % decrease in death or transfer to ICU (PE)
      • suggested 53 % decrease in deaths
      When we analyzed mortality separately, older age, lower PaO2/FiO2 ratio, and the use of HFNC but not remdesivir orbaricitinib were associated with reduced mortality. Baricitinib was not associated with shorter time to improvement

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

       

      - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons